查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589343

失智症藥物市場：依適應症、藥物類別分類 - 2025-2030 年全球預測

Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年失智症藥物市場價值為98億美元，預計到2024年將達到107.8億美元，複合年成長率為10.39%，到2030年將達到195.8億美元。

失智症治療藥物市場範圍主要包括旨在治療和管理失智症相關症狀的各種治療方法，例如阿茲海默症、血管性失智症、路易氏體失智症和額顳葉治療性介入。全球失智症盛行率不斷上升，迫切需要提高意識並減輕失智症的社會和家庭負擔，這推動了對這些藥物的需求。最終用途主要是症狀管理和減緩疾病進展，包括醫院、診所和專科護理中心。市場成長受到人口老化、生技進步和研發投資增加等因素的影響。此外，政府措施和醫療保健基礎設施發展是市場擴張的催化劑。最近的潛在商機包括開發針對潛在病理過程的疾病修正治療，例如Tau和 BETA-澱粉樣蛋白積累，以及旨在支持認知復健的新數位療法。為了利用這些機會，鼓勵相關人員投資個人化醫療方法並在藥物開發中利用人工智慧技術。然而，市場開拓面臨藥物開發高成本、監管核准流程冗長以及失智症異質性導致的臨床試驗設計挑戰等限制。此外，現有治療方法的安全性和有效性問題也構成了障礙。克服這些挑戰需要學術界、工業界和監管機構之間的密切合作。潛在的創新領域包括早期檢測的生物標記研究、與藥物治療相結合的非藥物干預以及探索腸腦軸作為新的治療標靶。市場的本質是動態和競爭的，其特點是技術的快速進步和對以患者為中心的護理的日益重視。為了取得成功，公司應優先考慮適應性，繼續探索未滿足的需求，並擴大夥伴關係，以培育失智症管理的全人解決方案。

主要市場統計
基準年[2023] 98億美元
預測年份 [2024] 107.8億美元
預測年份 [2030] 195.8億美元
複合年成長率（%） 10.39%

市場動態：揭示快速發展的失智症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變失智症治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加
    • 阿茲海默症率增加
    • 政府對阿茲海默症的資助和宣傳計劃
  • 市場限制因素
    • 研發成本上升
  • 市場機會
    • 透過提供安全可靠的藥品，線上藥局服務持續受歡迎
    • 新藥和治療方法的進展
    • 透過阿茲海默症和相關失智症治療方法和生物標記開發的進步創造資金籌措機會
  • 市場挑戰
    • 病理和發病機轉複雜，缺乏早期檢測的生物標記

波特五力：駕馭失智症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解失智症治療市場的外在影響

外部宏觀環境因素在塑造失智症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解失智症治療藥物市場的競爭狀況

失智症治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 失智症藥物市場定位失智症供應商績效評估

FPNV 定位矩陣是評估失智症治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪失智症治療市場的成功之路

失智症治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口老化加劇
      • 阿茲海默症的發生率增加
      • 政府對阿茲海默症的資助和宣傳計劃
    • 抑制因素
      • 研究和藥物開發成本高
    • 機會
      • 透過提供安全可靠的藥品，線上藥局服務持續受歡迎。
      • 新藥和治療方法的進展
      • 推動阿茲海默症和相關失智症的治療方法和生物標記的開發創造了資金籌措機會。
    • 任務
      • 病理學和發病機制複雜，並且沒有用於早期檢測該疾病的生物標記。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依適應症分類的失智症治療藥物市場

  • 阿茲海默症
  • 路易氏體失智症
  • 帕金森氏症失智症
  • 血管失智症

第7章依藥物類別分類的失智症治療藥物市場

  • 膽鹼酯酶抑制劑
  • 麩胺酸抑制劑
  • 單胺氧化酶抑制劑

第8章北美和南美失智症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區失智症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的失智症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Anavex Life Sciences Corp.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Forest Laboratories, Inc.
  • Janssen Global Services, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Quidel Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Zydus Cadila
Product Code: MRR-FD3F12D54013

The Dementia Drugs Market was valued at USD 9.80 billion in 2023, expected to reach USD 10.78 billion in 2024, and is projected to grow at a CAGR of 10.39%, to USD 19.58 billion by 2030.

The scope of the dementia drugs market encompasses various therapeutic interventions designed to treat and manage symptoms associated with dementia, mainly Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal disorders. The necessity of these drugs is driven by the increasing prevalence of dementia globally, heightened awareness, and the urgent need to alleviate the societal and familial burdens of the disease. Applications primarily include symptom management and slowing disease progression, with end-use markets involving hospitals, clinics, and specialized care centers. Market growth is influenced by factors such as an aging population, advancements in biotechnology, and increased R&D investments. Furthermore, governmental initiatives and supportive healthcare infrastructure serve as catalysts for market expansion. Recent potential opportunities include the development of disease-modifying therapies that target underlying pathological processes, such as tau and beta-amyloid accumulations, as well as emerging digital therapeutics aiming to support cognitive rehabilitation. To capitalize on these opportunities, stakeholders are encouraged to invest in personalized medicine approaches and leverage AI technologies in drug development. However, the market faces limitations like high costs of drug development, lengthy regulatory approval processes, and challenges in clinical trial designs due to the heterogeneous nature of dementia. Moreover, safety and efficacy concerns regarding existing treatments present obstacles. Overcoming these challenges requires strong collaboration between academia, industry, and regulatory bodies. Potential areas for innovation include biomarker research for early detection, non-pharmacological interventions paired with pharmacotherapy, and exploring the gut-brain axis as a novel therapeutic target. The nature of the market is dynamic and competitive, characterized by rapid technological advancements and a growing emphasis on patient-centric care. To thrive, companies should prioritize adaptability, continue exploring unmet needs, and expand partnerships to foster holistic solutions for dementia management.

KEY MARKET STATISTICS
Base Year [2023] USD 9.80 billion
Estimated Year [2024] USD 10.78 billion
Forecast Year [2030] USD 19.58 billion
CAGR (%) 10.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dementia Drugs Market

The Dementia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing geriatric population base
    • Increase in prevalence of Alzheimer disease
    • Government funding & awareness programs for Alzheimer disease
  • Market Restraints
    • High costs of research and drug development
  • Market Opportunities
    • Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
    • Advancement of new drugs and treatments
    • Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
  • Market Challenges
    • Complex pathology and etiology and no biomarkers for early detection of the disease

Porter's Five Forces: A Strategic Tool for Navigating the Dementia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dementia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dementia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dementia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dementia Drugs Market

A detailed market share analysis in the Dementia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dementia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dementia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dementia Drugs Market

A strategic analysis of the Dementia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dementia Drugs Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., AstraZeneca PLC, Aurobindo Pharma Limited, Biogen Inc., Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Quidel Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indications, market is studied across Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, and Vascular Dementia.
  • Based on Drug Class, market is studied across Cholinesterase Inhibitors, Glutamate Inhibitors, and MAO Inhibitors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population base
      • 5.1.1.2. Increase in prevalence of Alzheimer disease
      • 5.1.1.3. Government funding & awareness programs for Alzheimer disease
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of research and drug development
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
      • 5.1.3.2. Advancement of new drugs and treatments
      • 5.1.3.3. Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex pathology and etiology and no biomarkers for early detection of the disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dementia Drugs Market, by Indications

  • 6.1. Introduction
  • 6.2. Alzheimer's Disease
  • 6.3. Lewy Body Dementia
  • 6.4. Parkinsons Disease Dementia
  • 6.5. Vascular Dementia

7. Dementia Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Cholinesterase Inhibitors
  • 7.3. Glutamate Inhibitors
  • 7.4. MAO Inhibitors

8. Americas Dementia Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Dementia Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Dementia Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anavex Life Sciences Corp.
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Biogen Inc.
  • 5. Eisai Co., Ltd
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. Forest Laboratories, Inc.
  • 9. Janssen Global Services, LLC
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Pfizer, Inc.
  • 13. Quidel Corporation
  • 14. Sanofi S.A.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Valeant Pharmaceuticals International, Inc.
  • 17. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. DEMENTIA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DEMENTIA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DEMENTIA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LEWY BODY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PARKINSONS DISEASE DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MAO INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023